In a recent review article pub­lished in the journal Clinical Cancer Re­search, two myeloma experts from the Dana-Farber Cancer In­sti­tute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treat­ment of mul­ti­ple myeloma.

In their article, the experts discuss newer ther­a­pies that appear to be promising in clin­i­cal and pre­clin­i­cal stud­ies.

According to the physicians, com­bi­na­tion ther­a­pies that spe­cif­i­cally target a patient’s ge­netic form of the dis­ease will be re­quired for long-term dis­ease con­trol and ultimately a cure.

Some Historical Perspective

In their review article, Drs. Munshi and …

Results from a Phase 1 study indicate that tabalumab in combination with Velcade demonstrates both efficacy and safety in myeloma patients who have relapsed after several previous therapies.

Dr. Nooper Raje from Massachusetts General Hospital in Boston presented the results of the study at the American Society of Hematology (ASH) annual meeting earlier this month. She explained that tabalumab was very promising in this particular patient population, and added that “this was a very well tolerated regimen.”

However, Dr. Raje emphasized that further study of tabalumab at higher doses and in combination …

This year’s American Society of Hematology (ASH) meeting con­tinues in Atlanta.  Yesterday was the third day of the meeting and the busiest day in terms of myeloma-related presentations.  It was packed full of both oral and poster presentations.

There were so many myeloma-related talks given yesterday that many of them were held simultaneously.  The Beacon will therefore summarize presentations from the four most important sessions in updates such as this one.

This update covers presentations from the second of the four key oral presentation sessions.  An update published yesterday covers presentations from …

During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clin­i­cal trials involving a number of poten­tial new drugs under devel­op­ment for the treat­ment of multiple myeloma.

In particular, results for newer, lesser known agents that are in the early stages of clin­i­cal devel­op­ment will take center stage. These agents in­clude ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.

According to the recently …